Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases

Opinion statement Metastatic castrate-resistant prostate cancer (CRPC) refers to the disease state in which metastatic prostate cancer fails to respond to androgen deprivation therapy (ADT). This can be manifest as a rising PSA, increase in radiographically measurable disease, or progression of clin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current treatment options in oncology 2015-03, Vol.16 (3), p.325-325, Article 11
Hauptverfasser:	Blacksburg, Seth R., Witten, Matthew R., Haas, Jonathan A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone Density Conservation Agents - administration & dosage Bone Neoplasms - diagnostic imaging Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Combined Modality Therapy Disease Progression Genitourinary Cancers (W Oh and M Galsky Humans Male Medicine Medicine & Public Health Oncology Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radionuclide Imaging Radiopharmaceuticals - administration & dosage Section Editors Tomography, X-Ray Computed Topical Collection on Genitourinary Cancers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!